Home > Boards > US OTC > Medical - Drugs > Revive Therapeutics Ltd (RVVTF)

I added a little, not a lot as

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
LonghornSean Member Profile
 
Followed By 9
Posts 652
Boards Moderated 0
Alias Born 01/21/18
160x600 placeholder
Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF InvestorsHub NewsWire - 9/22/2021 7:30:00 AM
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer InvestorsHub NewsWire - 8/18/2021 6:00:00 AM
Revive Confirms No Material Undisclosed Information InvestorsHub NewsWire - 8/12/2021 9:56:48 AM
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline InvestorsHub NewsWire - 8/10/2021 8:52:12 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19 InvestorsHub NewsWire - 7/15/2021 2:47:32 PM
Revive Therapeutics provides update on late-stage bucillamine COVID-19 trial Seeking Alpha - 7/15/2021 1:44:58 PM
Revive Therapeutics Approved to Trade on the OTCQB Market InvestorsHub NewsWire - 6/28/2021 8:00:00 AM
Revive Therapeutics gets approval to trade on OTCQB Market Seeking Alpha - 6/25/2021 3:56:50 PM
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics InvestorsHub NewsWire - 6/17/2021 8:59:57 AM
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India InvestorsHub NewsWire - 6/8/2021 9:12:52 AM
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip InvestorsHub NewsWire - 5/17/2021 9:48:35 AM
Revive Therapeutics inks feasibility agreement with LTS Lohmann Seeking Alpha - 5/17/2021 9:30:38 AM
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 InvestorsHub NewsWire - 5/3/2021 9:32:33 AM
Revive inks research agreement to explore use of Bucillamine in treating severe COVID-19 Seeking Alpha - 5/3/2021 9:27:48 AM
Revive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury InvestorsHub NewsWire - 4/27/2021 9:51:20 AM
Revive files for FDA orphan drug status for psilocybin in traumatic brain injury Seeking Alpha - 4/27/2021 9:33:08 AM
Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....cont InvestorsHub NewsWire - 4/22/2021 8:26:06 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 InvestorsHub NewsWire - 3/24/2021 9:15:00 AM
Revive Therapeutics provides update on late-stage Bucillamine study in COVID-19 Seeking Alpha - 3/24/2021 9:08:15 AM
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...Cont InvestorsHub NewsWire - 3/19/2021 7:56:39 AM
Revive Therapeutics posts positive data from pre-clinical psilocybin brain injury study Seeking Alpha - 3/19/2021 7:37:00 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...Cont InvestorsHub NewsWire - 2/26/2021 9:01:27 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...Cont InvestorsHub NewsWire - 2/26/2021 9:01:27 AM
Revive Therapeutics Acquires Unique Psilocybin Assets InvestorsHub NewsWire - 2/17/2021 9:53:14 AM
Revive Therapeutics acquires psilocybin assets for C$10M Seeking Alpha - 2/17/2021 9:38:20 AM
LonghornSean   Tuesday, 06/08/21 04:18:37 PM
Re: Gatorca post# 26702
Post # of 28765 
I added a little, not a lot as I'm pretty full as it is.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences